Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

Commentary
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

In a conversation with CancerNetwork®, Sarah Donahue, MPH, NP, discussed strategies for managing adverse effects (AEs) associated with different drug classes for patients with metastatic breast cancer, ranging from antibody drug conjugates (ADCs) to CDK4/6 inhibitors.

With respect to ADCs, Donahue, a nurse practitioner at University of California, San Francisco, and member of the Oncology Nursing Society, highlighted common AEs following treatment with trastuzumab deruxtecan (T-DXd; Enhertu) and sacituzumab govitecan-hziy (Trodelvy). In particular, she spoke about the necessity of managing nausea associated with T-DXd by helping patients schedule doses with antiemetic drugs, as well as mitigating fatigue and improving quality of life in the process. For those who are treated with sacituzumab govitecan, Donahue spoke about mitigating abdominal cramping at her infusion center and administering loperamide to help patients manage acute diarrhea.

Donahue also discussed her methods for managing toxicity related to CDK4/6 inhibitors including palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenios). Among patients with hormone receptor (HR)–positive breast cancer, treatment with palbociclib and ribociclib, when given in combination with hormonal therapy, may result in fatigue, hot flashes, and arthralgia. According to Donahue, encouraging patients to exercise often may combat fatigue while mitigating arthralgia associated with an aromatase inhibitor. Moreover, she stated that loperamide may help manage potential diarrhea following treatment with abemaciclib.

Overall, Donahue underscored the importance of keeping patients on treatments with CDK4/6 inhibitors and other treatments by being communicative with them regarding the potential to alleviate AEs. She suggested that such openness may give patients the confidence to ask providers for guidance on how to manage their disease.

“The main thing that I find most helpful for my patients is to explain the potential [adverse] effects, explain that there’s something that we can do about them—that we can intervene. If they reach out to us sooner, we can help them more,” Donahue concluded. “I hope that the providers who are listening to this now can help to empower their patients to reach out and to ask for advice. That’s the best thing that they can do to keep them on these medications longer. They can work well; we can show that in studies. But if we can’t keep [patients] on the medications, then what are we doing?”

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.